Cargando…
Anti-Xa monitoring improves low-molecular-weight heparin effectiveness in patients with SARS-CoV-2 infection
Autores principales: | Trunfio, Mattia, Salvador, Elena, Cabodi, Daniela, Marinaro, Letizia, Alcantarini, Chiara, Gaviraghi, Alberto, Trentalange, Alice, Lipani, Filippo, Sciascia, Savino, Roccatello, Dario, Bonora, Stefano, Di Perri, Giovanni, Calcagno, Andrea |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7543686/ https://www.ncbi.nlm.nih.gov/pubmed/33049598 http://dx.doi.org/10.1016/j.thromres.2020.09.039 |
Ejemplares similares
-
Discordance in activated partial thromboplastin time and anti-factor Xa levels in COVID-19 patients on heparin therapy
por: Lawlor, Matthew, et al.
Publicado: (2021) -
Coagulopathy monitoring and anticoagulation management in COVID-19 patients on ECMO: Advantages of a heparin anti-Xa-based titration strategy
por: Rhoades, Ruben, et al.
Publicado: (2021) -
The Manifesto of Pharmacoenosis: Merging HIV Pharmacology into Pathocoenosis and Syndemics in Developing Countries
por: Trunfio, Mattia, et al.
Publicado: (2021) -
Lowering SARS-CoV-2 viral load might affect transmission but not disease severity in secondary cases
por: Trunfio, Mattia, et al.
Publicado: (2021) -
Antiretroviral Levels in the Cerebrospinal Fluid: The Effect of Inflammation and Genetic Variants
por: Cusato, Jessica, et al.
Publicado: (2023)